One significant problem in traumatic brain injury is that secondary cell death occurs when the injured cells block the path for the other cells to get oxygen. One product that is used extensively in other countries but not the USA is Piracetam. It is interesting that research in pub med is showing promise for efficacy in human trials. There have been rat, rabbit, and fruit fly trials available for years but there is a lot that can differ between these and seeing actual human benefit.

I used this product to good effect many years ago without side effects and am encouraged to see studies supporting its effectiveness. The alternatives available to many people with TBI as far as psychotropic meds to restore some measure of function are concerned can sometimes have unexpected reactions or be of no effect.

Piracetam has been shown to alter the physical properties of the plasma membrane by increasing its fluidity and by protecting the cell against hypoxia. It increases red cell deformability and normalizes aggregation of hyperactive platelets according to Winnicka K, Tomasiak M, Bielawska A (2005) They are saying treatment with piracetam improves learning, memory, brain metabolism, and capacity by the interaction of this molecule with the membrane phospholipids to restore membrane fluidity . The graph below is from smart publications

The positive therapeutic effects of piracetam on cognitive (memory, attention, executive functions) and motor (coordination) functions as well as the speed of cognitive and motor performance were demonstrated in a study done by Zh Nevrol Psikhiatr Im S S Korsakova. 2008 for adolescents who sustained TBI’s.

Its efficacy is documented in cognitive disorders and dementia, vertigo, cortical myoclonus, dyslexia, and sickle cell anemia according to Winblad B (2005).

The results of a meta-analysis Waegemans T, Wilsher CR, Danniau A, Ferris SH, Kurz A, Winblad B. (2002) demonstrate a difference between those individuals treated with piracetam and those given placebo, both as significant odds ratio and as a favourable number needed to treat. While there may be problems in meta-analyses and the interpretation of the statistical results, the results of this analysis provide compelling evidence for the global efficacy of piracetam in a diverse group of older subjects with cognitive impairment.

This post does not in any way constitute any medical advice or recommendation. These posts are educational only to share with others some of the direction research is taking. Any medical information gained online should be supported and endorsed by your own doctor.

[The consequences of closed traumatic brain injury and piracetam efficacy in their treatment in adolescents]
Zavadenko NN, Guzilova LS.
Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(3):43-8. Russian.
PMID: 18427539 [PubMed - indexed for MEDLINE]
Related Articles

Piracetam–an old drug with novel properties?
Winnicka K, Tomasiak M, Bielawska A.
Acta Pol Pharm. 2005 Sep-Oct;62(5):405-9. Review.
PMID: 16459490 [PubMed - indexed for MEDLINE]
Related Articles

Piracetam: a review of pharmacological properties and clinical uses.
Winblad B.
CNS Drug Rev. 2005 Summer;11(2):169-82. Review.
PMID: 16007238 [PubMed - indexed for MEDLINE]
Related Articles

Clinical efficacy of piracetam in cognitive impairment: a meta-analysis.
Waegemans T, Wilsher CR, Danniau A, Ferris SH, Kurz A, Winblad B.
Dement Geriatr Cogn Disord. 2002;13(4):217-24.
PMID: 12006732 [PubMed - indexed for MEDLINE]
Related Articles